Stephen Gould
Geen lopende functies
Vermogen: 31 863 $ op 31-03-2024
Profiel
Stephen Gould worked as an Executive Director of Translational Oncology at Genentech, Inc. and as a Senior Director at Curis, Inc. He also served as the Chief Scientific Officer at Atreca, Inc. for a year.
Gould holds a doctorate degree from the University of Connecticut Health Center.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ATRECA, INC. CLASS A
1.04% | 02-08-2023 | 398 293 ( 1.04% ) | 31 863 $ | 31-03-2024 |
Eerdere bekende functies van Stephen Gould
| Bedrijven | Functie | Einde |
|---|---|---|
| ATRECA, INC. | Chief Tech/Sci/R&D Officer | 31-12-2023 |
| CURIS, INC. | Director/Board Member | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Opleiding van Stephen Gould
| University of Connecticut Health Center | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CURIS, INC. | Health Technology |
| ATRECA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
